Insulet (NasdaqGS:PODD) experienced a 5% increase in share price over the past week, a period marked by significant financial advancements and product developments. The company's successful closure of ...

花旗：维持Insulet(PODD.US)评级，由买入调整至买入评级, 目标价由310.00美元调整至355.00美元。 银休特（PODD.US）公司简介：Insulet成立于2000年，公司的 ...

Insulet shows bullish trends with strong growth, favorable Wall Street ratings, and a 3.2:1 reward-risk ratio. Read more on ...

Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This ...

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Insulet Corporation PODD recently made its Omnipod 5 Automated ... Omnipod 5 was first introduced in the United States in 2022 and has demonstrated strong clinical results with real-world evidence.

Insulet Corporation’s RADIANT study shows glycaemic improvements with Omnipod 5 automated insulin delivery system: Action, Massachusetts Friday, March 21, 2025, 18:00 Hrs [IST] ...

Shares of Insulet Co. (NASDAQ:PODD – Get Free Report) have received an average rating of “Moderate Buy” from the seventeen research firms that are currently covering the company, MarketBeat ...

Victory Capital Management Inc. trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 1.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned ...